Emerging Trends in Targeted Molecular Therapies for Inflammatory Bowel Disease: Biologics and Small Molecules - PubMed
2 hours ago
- #inflammatory bowel disease
- #biologics and small molecules
- #targeted molecular therapies
- This review discusses advancements in targeted molecular therapies for inflammatory bowel disease (IBD), focusing on biologics and small molecules.
- Biologic therapies, including anti-TNF agents, integrin inhibitors, and interleukin inhibitors, have improved remission and mucosal healing, but face challenges like immunogenicity and high costs.
- Small-molecule drugs, such as JAK inhibitors and S1P receptor modulators, offer oral alternatives with rapid onset, though they come with systemic safety concerns.
- Novel therapies like TYK2 and HDAC inhibitors, and nanotechnology-based delivery systems, show promising potential in early trials.
- Accessibility and affordability remain major obstacles globally, emphasizing the need for biosimilars and international policy support.
- Targeted molecular therapies have revolutionized IBD management by enabling precision treatment with better efficacy and tolerability, with future efforts focusing on reducing drug resistance, costs, and integrating personalized medicine.